Altered reactivity of tertiary mesenteric arteries following acute myocardial ischemia

Journal of Vascular Research

Volumn 50, Issue 2, 2013, Pages 100-108

  Han, Young Soo ^a   Brozovich, Frank V ^a  

^a MAYO CLINIC   (United States)

Author keywords

8 Bromo cGMP; Acetylcholine; Mesenteric artery; Myosin phosphatase targeting subunit 1; Nonmuscle myosin

Indexed keywords

8 BROMO CYCLIC GMP; ACETYLCHOLINE; ADENYLATE CYCLASE; ALPHA ACTIN; CYCLIC GMP; DESMIN; GLUTAMATE DEHYDROGENASE; MYOSIN LIGHT CHAIN; MYOSIN PHOSPHATASE TARGETING SUBUNIT 1; NITRIC OXIDE; PROTEIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BLOOD VESSEL TONE; CARDIOVASCULAR RESPONSE; HEART DEPOLARIZATION; HEART MUSCLE ISCHEMIA; IMMUNOBLOTTING; LIGHT CHAIN; MALE; MASS SPECTROMETRY; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SMOOTH MUSCLE RELAXATION; TERTIARY MESENTERIC ARTERY; TWO DIMENSIONAL ELECTROPHORESIS; UBIQUITINATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ACETYLCHOLINE; ACUTE DISEASE; ANIMALS; BIOMECHANICS; CYCLIC GMP; ENZYME INDUCTION; MALE; MEMBRANE POTENTIALS; MESENTERIC ARTERIES; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL INFARCTION; MYOSIN LIGHT CHAINS; NITRIC OXIDE; PHOSPHORYLATION; POTASSIUM CHLORIDE; PROTEIN PHOSPHATASE 1; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, SPRAGUE-DAWLEY; UBIQUITINATION; VASODILATION;

EID: 84869235812     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000343015     Document Type: Article

References (52)

1. Fagan SC, Hess DC, Hohnadel EJ, Pollock DM, Ergul A: Targets for vascular protection after acute ischemic stroke. Stroke 2004; 35: 2220-2225.
2. Fernandez N, Martinez MA, Climent B, Garcia-Villalon AL, Monge L, Sanz E: Coronary reactivity to endothelin-1 during partial ischemia and reperfusion in anesthetized goats. Role of nitric oxide and prostanoids. Eur J Pharmacol 2002; 457: 161-168.
3. Francis GS, Cohn JN: Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB J 1990; 4: 3068-3075.
4. Negrao CE, Hamilton MA, Fonarow GC, Hage A, Moriguchi JD, Middlekauff HR: Impaired endothelium-mediated vasodilation is not the principal cause of vasoconstriction in heart failure. Am J Physiol 2000; 278:H168-H174.
5. Gong MC, Cohen P, Kitazawa T, Ikebe M, Masuo M, Somlyo AP: Myosin light chain phosphatase activities and the effects of phosphatase inhibitors in tonic and phasic smooth muscle. J Biol Chem 1992; 267: 14662-14668.
6. Ogut O, Brozovich FV: Determinants of the contractile properties in the embryonic chicken gizzard and aorta. Am J Physiol 2000; 279:C1722-C1732.
7. Ogut O, Yuen SL, Brozovich FV: Regulation of the smooth muscle contractile phenotype by nonmuscle myosin. J Muscle Res Cell Motil 2007; 28: 409-414.
8. Ekman M, Fagher K, Wede M, Stakeberg K, Arner A: Decreased phosphatase activity, increased Ca2+ sensitivity, and myosin light chain phosphorylation in urinary bladder smooth muscle of newborn mice. J Gen Physiol 2005; 125: 187-196.
9. Furchgott RF: Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep 1999; 19: 235-251.
10. Karim SM, Rhee AY, Given AM, Faulx MD, Hoit BD, Brozovich FV: Vascular reactivity in heart failure. Role of myosin light chain phosphatase. Circ Res 2004; 95: 612-619.
11. Chen FC, Ogut O, Rhee AY, Hoit BD, Brozovich FV: Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation. J Mol Cell Cardiol 2006; 41: 488-495.
12. Ararat E, Brozovich FV: Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression. PLoS One 2009; 4:e5144.
13. Huang QQ, Fisher SA, Brozovich FV: Unzipping the role of myosin light chain phosphatase in smooth muscle cell relaxation. J Biol Chem 2004; 279: 597-603.
14. Chen FC, Ogut O: Decline of contractility during ischemia-reperfusion injury: actin glutathionylation and its effect on allosteric interaction with tropomyosin. Am J Physiol Cell Physiol 2006; 290:C719-C727.
15. Han YS, Ogut O: Regulation of fibre contraction in a rat model of myocardial ischemia. PLoS One 2010; 5:e9528.
16. Christopher B, Pizarro GO, Nicholson B, Yuen S, Hoit BD, Ogut O: Reduced force production during low blood flow to the heart correlates with altered troponin I phosphorylation. J Muscle Res Cell Motil 2009; 30: 111-123.
17. Mulvany MJ, Halpern W: Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977; 41: 19-26.
18. Mulvany MJ, Nilsson H, Flatman JA: Role of membrane potential in the response of rat small mesenteric arteries to exogenous noradrenaline stimulation. J Physiol 1982; 332: 363-373.
19. Mulvany MJ, Nilsson H, Flatman JA, Korsgaard N: Potentiating and depressive effects of ouabain and potassium-free solutions on rat mesenteric resistance vessels. Circ Res 1982; 51: 514-524.
20. Yuen SL, Ogut O, Brozovich FV: Nonmuscle myosin is regulated during smooth muscle contraction. Am J Physiol 2009; 297:H191-H199.
21. Richards CT, Ogut O, Brozovich FV: Agonist-induced force enhancement: the role of isoforms and phosphorylation of the myosin-targeting subunit of myosin light chain phosphatase. J Biol Chem 2002; 277: 4422-4427.
22. Golomb E, Ma X, Jana SS, Preston YA, Kawamoto S, Shoham NG: Identification and characterization of nonmuscle myosin II-C, a new member of the myosin II family. J Biol Chem 2004; 279: 2800-2808.
23. Phillips CL, Yamakawa K, Adelstein RS: Cloning of the cDNA encoding human nonmuscle myosin heavy chain-B and analysis of human tissues with isoform-specific antibodies. J Muscle Res Cell Motil 1995; 16: 379-389.
24. Wang F, Kovacs M, Hu A, Limouze J, Harvey EV, Sellers JR: Kinetic mechanism of nonmuscle myosin IIB: functional adaptations for tension generation and maintenance. J Biol Chem 2003; 278: 27439-27448.
25. Kovacs M, Wang F, Hu A, Zhang Y, Sellers JR: Functional divergence of human cytoplasmic myosin II: kinetic characterization of the non-muscle IIA isoform. J Biol Chem 2003; 278: 38132-38140.
26. Rhee AY, Ogut O, Brozovich FV: Nonmuscle myosin, force maintenance, and the tonic contractile phenotype in smooth muscle. Pflugers Arch 2006; 452: 766-774.
27. Limouze J, Straight AF, Mitchison T, Sellers JR: Specificity of blebbistatin, an inhibitor of myosin II. J Muscle Res Cell Motil 2004; 25: 337-341.
28. El-Yazbi AF, Johnson RP, Walsh EJ, Takeya K, Walsh MP, Cole WC: Pressure-dependent contribution of Rho kinase-mediated calcium sensitization in serotonin-evoked vasoconstriction of rat cerebral arteries. J Physiol 2010; 588: 1747-1762.
29. Walsh MP, Thornbury K, Cole WC, Sergeant G, Hollywood M, McHale N: Rho-associated kinase plays a role in rabbit urethral smooth muscle contraction, but not via enhanced myosin light chain phosphorylation. Am J Physiol Renal Physiol 2011; 300:F73-F85.
30. Alioua A, Tanaka Y, Wallner M, Hofmann F, Ruth P, Meera P: The large conductance, voltage-dependent, and calcium-sensitive K+ channel, Hslo, is a target of cGMP-dependent protein kinase phosphorylation in vivo. J Biol Chem 1998; 273: 32950-32956.
31. Schmidt HH, Lohmann SM, Walter U: The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochem Biophys Acta 1993; 1173: 153-175.
32. Fukao M, Mason HS, Britton FC, Kenyon JL, Horowitz B, Keef KD: Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine 1072. J Biol Chem 1999; 274: 10927-10935.
33. Dou D, Ma H, Zheng X, Ying L, Guo Y, Yu X, Gao Y: Degradation of leucine zipper-positive isoform of MYPT1 may contribute to development of nitrate tolerance. Cardiovasc Res 2010; 86: 151-159.
34. Ma H, He Q, Dou D, Zheng X, Ying L, Wu Y, Raj JU, Gao Y: Increased degradation of MYPT1 contributes to the development of tolerance to nitric oxide in porcine pulmonary artery. Am J Physiol Lung Cell Mol Physiol 2010; 299:L117-L123.
35. Ogut O, Brozovich FV: The potential role of MLC phosphatase and MAPK signalling in the pathogenesis of vascular dysfunction in heart failure. J Cell Mol Med 2008; 12: 2158-2164.
36. Kim HR, Appel S, Vetterkind S, Gangopadhyay SS, Morgan KG: Smooth muscle signalling pathways in health and disease. J Cell Mol Med 2008; 12: 2165-2180.
37. Aburto TK, Lajoie C, Morgan KG: Mechanisms of signal transduction during alpha 2-adrenergic receptor-mediated contraction of vascular smooth muscle. Circ Res 1993; 72: 778-785.
38. Suzuki K, Hata S, Kawabata Y, Sorimachi H: Structure, activation, and biology of calpain. Diabetes 2004; 53(suppl 1):S12-S18.
39. Coux O, Tanaka K, Goldberg AL: Structure and functions of the 20s and 26s proteasomes. Annu Rev Biochem 1996; 65: 801-847.
40. Zong C, Young GW, Wang Y, Lu H, Deng N, Drews O, Ping P: Two-dimensional electrophoresis-based characterization of posttranslational modifications of mammalian 20S proteasome complexes. Proteomics 2008; 8: 5025-5037.
41. Drews O, Tsukamoto O, Liem D, Streicher J, Wang Y, Ping P: Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. Circ Res 2010; 107: 1094-1101.
42. Kapadia MR, Eng JW, Jiang Q, Stoyanovsky DA, Kibbe MR: Nitric oxide regulates the 26S proteasome in vascular smooth muscle cells. Nitric Oxide 2009; 20: 279-288.
43. Zhang JC, Kim S, Helmke BP, Yu WW, Du KL, Lu MM, Strobeck M, Yu Q, Parmacek MS: Analysis of SM22alpha-deficient mice reveals unanticipated insights into smooth muscle cell differentiation and function. Mol Cell Biol 2001; 21: 1336-1344.
44. Shapland C, Hsuan JJ, Totty NF, Lawson D: Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein. J Cell Biol 1993; 121: 1065-1073.
45. Ali F, Chin L, Pare PD, Seow CY: Mechanism of partial adaptation in airway smooth muscle after a step change in length. J Appl Physiol 2007; 103: 569-577.
46. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
47. Bolli R, Marban E: Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999; 79: 609-634.
48. Freis ED, Schnaper HW, Johnson RL, Schreiner GE: Hemodynamic alterations in acute myocardial infarction. I. Cardiac output, mean arterial pressure, total peripheral resistance, central and total blood volumes, venous pressure and average circulation time. J Clin Invest 1952; 31: 131-140.
49. Khatri JJ, Joyce KM, Brozovich FV, Fisher SA: Role of myosin phosphatase isoforms in cGMP-mediated smooth muscle relaxation. J Biol Chem 2001; 276: 37250-37257.
50. Payne MC, Zhang HY, Prosdocimo T, Joyce KM, Koga Y, Ikebe M, Fisher SA: Myosin phosphatase isoform switching in vascular smooth muscle development. J Mol Cell Cardiol 2006; 40: 274-282.
51. Payne MC, Zhang HY, Shirasawa Y, Koga Y, Ikebe M, Benoit JN, Fisher SA: Dynamic changes in expression of myosin phosphatase in a model of portal hypertension. Am J Physiol 2004; 286:H1801-H1810.
52. Lu Y, Zhang H, Gokina N, Mandala M, Sato O, Ikebe M, Osol G, Fisher SA: Uterine artery myosin phosphatase isoform switching and increased sensitivity to SNP in a rat L-NAME model of hypertension of pregnancy. Am J Physiol Cell Physiol 2008; 294:C564-C571.